twitter test

Article

Can circulating tumor DNA predict relapse in breast cancer?

- Dr. Muin Khoury (@DrKhouryCDC) August 30, 2015

Cool technology. Not quite ready for primetime but soon. Blood test could predict breast cancer relapse @cbsnews

- Hal Burstein, MD (@DrHBurstein) August 27, 2015

MT @NEJM: Daratumumab elicited impressive responses in pretreated myeloma pts. #mmsm

- Michael Fisch (@fischmd) August 27, 2015

Daratumumab is safe and has encouraging activity in patients with heavily pretreated and refractory myeloma

- Muzaffar Qazilbash (@Transplant_Doc) August 26, 2015

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Related Content
55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?

55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?

Natalie Garver;Valerie L. Staradub, MD;Christopher Verdone;Kelly Mackessy;Alexandra Haraczy;Lianteng Zhi
May 20th 2025
Article
Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

The FDA’s ODAC convened to discuss the potentially inconsistent treatment effects of glofitamab between regional subgroups in the phase 3 STARGLO trial.

FDA ODAC Votes 8-to-1 Against Applicability of Glofitamab DLBCL Data

Russ Conroy
May 20th 2025
Article

The FDA’s ODAC convened to discuss the potentially inconsistent treatment effects of glofitamab between regional subgroups in the phase 3 STARGLO trial.

A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Data from an ongoing phase 1a/1b trial evaluating ZL-1310 in ES-SCLC will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.

ZL-1310 Receives FDA Fast Track Designation for Extensive-Stage SCLC

Roman Fabbricatore
May 20th 2025
Article

3 Things You Should Know About Advances in CLL Management

3 Things You Should Know About Advances in CLL Management

ONCOLOGY Staff
May 20th 2025
Article

Care for patients with chronic lymphocytic leukemia continues to evolve via novel targeted therapies. Here are 3 things every cancer care specialist should know about treating CLL.